Lumonus, the leader in AI-based cancer radiation therapy treatments, has made an important strategic alliance with one of the most renowned centers Memorial Sloan Kettering Cancer Center (MSK) dedicated to cancer research and treatment in the world. The objective of the collaboration is to move forward in the process of validating the new technology for medical applications.
Advancing the Standard of Care Through AI
Radiation treatment still stands as one of the most essential methods of treating various types of cancer. However, the process itself may involve certain complexities. In order to solve this issue, Lumonus has decided to rely on artificial intelligence for optimizing the treatment planning process.
The purpose of the joint effort is to improve the software of Lumonus in terms of applicability in a high-throughput setting to ensure the best quality work for top oncologists and reduce the time period between diagnosis and the start of radiation therapy.
Also Read: Tampa General Hospital and Hyro Partner to Transform Call Center with Voice AI
Objectives and Key Benefits
The following strategic goals stand at the core of this collaboration:
- Optimization of Workflow through the use of AI: automation of contouring and dosage distribution procedures will help doctors concentrate on patients.
- Maximum Precision: improving the precision of the radiation treatment to reduce the impact on healthy tissue.
- Scalability: testing the effectiveness of the technology on multiple cases of cancer all over the world.
Perspectives from Leadership
“We are incredibly proud to collaborate with such a world-renowned institution that shares our commitment to innovation and patient care,” said Ido Wolf, CEO of Lumonus. “This partnership is a testament to the potential of our technology to revolutionize radiation therapy planning. By combining our AI-driven solutions with the clinical expertise of one of the world’s leading cancer centers, we are poised to set a new standard in treatment precision and efficiency, ultimately benefiting cancer patients worldwide.”
“This collaboration is a significant milestone in our mission to transform the cancer treatment landscape,” added Hanan Lewkowicz, Chairman of the Board of Lumonus. “The insights and feedback from this partnership will be invaluable as we continue to refine our platform and prepare for broader clinical adoption. We look forward to a successful collaboration that will drive the future of radiation therapy forward.”
